Evidence map›Paper›PMID 38939523›Full record

ReviewHealth care science2023

COVID-19 retreats and world recovers: A silver lining in the dark cloud.

Amol Chhatrapati Bisen, Sristi Agrawal, Sachin Nashik Sanap, Heamanth Ganesan Ravi Kumar, Nelam Kumar, Rajdeep Gupta, Rabi Sankar Bhatta

Abstract readReview
In one paragraph

Review in Health care science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amol Chhatrapati BisenPharmaceutics and Pharmacokinetics Division CSIR-Central Drug Research Institute Lucknow Uttar Pradesh India.ORCID https://orcid.org/0000-0003-4841-0140
Sristi AgrawalPharmaceutics and Pharmacokinetics Division CSIR-Central Drug Research Institute Lucknow Uttar Pradesh India.ORCID https://orcid.org/0009-0008-4656-131X
Sachin Nashik SanapPharmaceutics and Pharmacokinetics Division CSIR-Central Drug Research Institute Lucknow Uttar Pradesh India.ORCID https://orcid.org/0000-0002-1427-9247
Heamanth Ganesan Ravi KumarPharmaceutics and Pharmacokinetics Division CSIR-Central Drug Research Institute Lucknow Uttar Pradesh India.ORCID https://orcid.org/0009-0007-0020-5750
Nelam KumarBiochemistry and Structural Biology Division CSIR-Central Drug Research Institute Lucknow Uttar Pradesh India.ORCID https://orcid.org/0000-0003-3841-9838
Rajdeep GuptaPharmaceutics and Pharmacokinetics Division CSIR-Central Drug Research Institute Lucknow Uttar Pradesh India.
Rabi Sankar BhattaPharmaceutics and Pharmacokinetics Division CSIR-Central Drug Research Institute Lucknow Uttar Pradesh India.ORCID 0000-0003-4844-2388

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease (COVID-19), which the World Health Organization classified as the Sixth Public Health Emergency Of International Concern (PHEIC) on January 30, 2020, is no longer a PHEIC. Millions were affected due to unawareness. The increase in fatalities and shortage of medicine was the first outrage of COVID-19. As per the Johns Hopkins COVID-19 resource center database, it was observed that the disease has spread dynamically across 200+ nations worldwide affecting more than 600 million people from 2019 to 2023, and over thousands of people were victimized regularly at a 2% mortality rate (approx.). In the midway, the mutant variants of concern like omicron, and delta have also created havoc and caused significant impact on public health, global economy, and lifestyle. Since 2019, 3 years now passed and the dynamic disease statistics seem decelerated; moreover, the prevalence of COVID-19 is also fading. The Johns Hopkins resource center has also stopped recording the data of the global pandemic recently from March 10, 2023. Hence, based on the facts, we are presenting a concise report on the pandemic from 2019 to 2023, which includes a brief discussion of the global pandemic. We have highlighted global epidemiology, emphasizing the Indian COVID scenario, vaccination across the globe, and the psychosocial and geopolitical consequences of COVID-19 with a brief background to pathology, clinical management, and the worldwide response against triage. A lot has changed and still needs to change after three tough years of COVID-19. Even though science has progressed and advanced research in medicine is pointing toward future generations, there is no standard care supplied for COVID-19-like calamities. COVID-19 cases might have declined but its influence on the society is still stagnant. This COVID experience has taught us that, despite our bleak beginnings, there is always hope for the future and that we must act with foresight to improve things for future generations.

Indexed as

COVID‐19 impactCOVID‐19 pandemicepidemiologyIndiavaccinesworld

Identifiers

PMID38939523
PMCPMC11080794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.